Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvonne Grobben

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|August 30, 2024
Targeting amino acid-metabolizing enzymes for cancer immunotherapyYvonne Grobben
Cancers|February 11, 2023
Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1Yvonne Grobben, Judith E den Ouden, Cristina Aguado, et al.
Bioconjugate Chemistry|February 23, 2019
Installation of Trimethyllysine Analogs on Intact Histones via Cysteine AlkylationBas J G E Pieters, Jordi C J Hintzen, Yvonne Grobben, et al.
Journal of Structural Biology: X|July 11, 2020
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158Yvonne Grobben, Joost C M Uitdehaag, Nicole Willemsen-Seegers, et al.
Journal of Natural Products|July 4, 2025
Synthesis and Absolute Configuration of the Sesquiterpene Lactone EPD, a Natural Product with Broad Antitumor Cell Activity via a Unique Mechanism of ActionCaroline van Haaften, Jan Koek, Jaap D H van Eendenburg, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 19, 2020
High-Throughput Fluorescence-Based Activity Assay for Arginase-1Yvonne Grobben, Nicole Willemsen-Seegers, Joost C M Uitdehaag, et al.
Oncotarget|December 21, 2020
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascitesJudith E den Ouden, Guido J R Zaman, Jelle Dylus, et al.
Frontiers in Oncology|November 7, 2025
Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancersDaphne J F Kluitmans, Janneke J T M Melis, Esmee van den Bossche, et al.
Frontiers in Oncology|October 3, 2022
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Jeffrey J Kooijman, Wilhelmina E van Riel, Jelle Dylus, et al.
The FEBS Journal|January 20, 2021
Pharmacological validation of TDO as a target for Parkinson's diseasePaula Perez-Pardo, Yvonne Grobben, Nicole Willemsen-Seegers, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|August 30, 2024
Targeting amino acid-metabolizing enzymes for cancer immunotherapyYvonne Grobben
Cancers|February 11, 2023
Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1Yvonne Grobben, Judith E den Ouden, Cristina Aguado, et al.
Bioconjugate Chemistry|February 23, 2019
Installation of Trimethyllysine Analogs on Intact Histones via Cysteine AlkylationBas J G E Pieters, Jordi C J Hintzen, Yvonne Grobben, et al.
Journal of Structural Biology: X|July 11, 2020
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158Yvonne Grobben, Joost C M Uitdehaag, Nicole Willemsen-Seegers, et al.
Journal of Natural Products|July 4, 2025
Synthesis and Absolute Configuration of the Sesquiterpene Lactone EPD, a Natural Product with Broad Antitumor Cell Activity via a Unique Mechanism of ActionCaroline van Haaften, Jan Koek, Jaap D H van Eendenburg, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 19, 2020
High-Throughput Fluorescence-Based Activity Assay for Arginase-1Yvonne Grobben, Nicole Willemsen-Seegers, Joost C M Uitdehaag, et al.
Oncotarget|December 21, 2020
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascitesJudith E den Ouden, Guido J R Zaman, Jelle Dylus, et al.
Frontiers in Oncology|November 7, 2025
Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancersDaphne J F Kluitmans, Janneke J T M Melis, Esmee van den Bossche, et al.
Frontiers in Oncology|October 3, 2022
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Jeffrey J Kooijman, Wilhelmina E van Riel, Jelle Dylus, et al.
The FEBS Journal|January 20, 2021
Pharmacological validation of TDO as a target for Parkinson's diseasePaula Perez-Pardo, Yvonne Grobben, Nicole Willemsen-Seegers, et al.
Pageof 2